Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Beacon Therapeutics Limited currently manages 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner, PENNINGTON, KATIE LEIGH, who is also the busiest examiner with 1 pending office action. The prosecution is conducted within 1 distinct art unit.
The presence of 1 pending office action indicates a concentrated effort in the Biotechnology & Pharmaceuticals sector. The reliance on 1 distinct examiner means the current prosecution strategy is focused on a single point of review. This concentration allows for a highly specific prosecution approach but limits the diversity of examiner perspectives available to the company.
Practitioners should note that the 1 pending office action represents the total active engagement across the portfolio. The focus remains entirely within the Biotechnology & Pharmaceuticals area under a single examiner's review. This requires a targeted response to the specific requirements of PENNINGTON, KATIE LEIGH to resolve the pending matter in the 1 distinct art unit.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PENNINGTON, KATIE LEIGH | 1 | 31.8% | +58.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18656930 | PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS, AND METHODS FOR THE TREATMENT OF ACHROMATOPSIA AND OTHER DISEASES | PENNINGTON, KATIE LEIGH | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18656930 | PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS, AND METHODS FOR THE TREATMENT OF ACHROMATOPSIA AND OTHER DISEASES | PENNINGTON, KATIE LEIGH | — |
| Art Unit | Apps |
|---|---|
| 1634 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18656930 | PROMOTERS, EXPRESSION CASSETTES, VECTORS, KITS, AND METHODS FOR THE TREATMENT OF ACHROMATOPSIA AND OTHER DISEASES | PENNINGTON, KATIE LEIGH | 1634 | §102§112Other | Non-Final OA | — | Pending | May 07, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialBeacon Therapeutics Limited has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Katie Leigh Pennington has the most, with 1 of Beacon Therapeutics Limited's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
